Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

There are now seven CAR-T products approved on the US market, with Bristol Myers Squibb developing two of ... benefit both patients and the broader oncology market. However, for first movers ...

Its research and development efforts concentrate on the following six core therapeutic areas: cardiovascular, immunoscience, metabolics, neuroscience, oncology and virology. According to BMS ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

The NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical ...